Giiant Pharma Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 10

Giiant Pharma General Information

Description

Developer of gut-restricted, small molecule therapeutics designed to improve the tolerability and efficacy of treatments for inflammatory bowel diseases (IBD). The company's platform offers precision delivery technology, utilizing the gut microbiota to bioactivate and release drugs in specific lower GI tract locations and releases the specific active form in the colon at the site of inflammation, enabling IBD patients to experience safe and effective treatments with minimal systemic exposure.

Contact Information

Website
www.giiant.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 630 René-Lévesque Boulevard West
  • 20th Floor
  • Montreal, Quebec H3B 1S6
  • Canada
+1 (514)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 630 René-Lévesque Boulevard West
  • 20th Floor
  • Montreal, Quebec H3B 1S6
  • Canada
+1 (514)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Giiant Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private Completed Pre-Clinical Trials
2. Seed Round 30-Jun-2021 Completed Pre-Clinical Trials
1. Seed Round 18-Dec-2020 Completed Startup
To view Giiant Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Giiant Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gut-restricted, small molecule therapeutics designed to improve the tolerability and efficacy of treatments
Drug Discovery
Montreal, Canada
4 As of 2026

Markham, Canada
 

Wayne, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Giiant Pharma Competitors (4)

One of Giiant Pharma’s 4 competitors is Edesa Biotech, a Formerly VC-backed company based in Markham, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Edesa Biotech Formerly VC-backed Markham, Canada
Aclaris Therapeutics Formerly VC-backed Wayne, PA
Athersys Formerly VC-backed Cleveland, OH
Pfizer Corporation New York, NY
To view Giiant Pharma’s complete competitors history, request access »

Giiant Pharma Patents

Giiant Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2989065-T3 Bioactivated pde4 inhibitor precursors from the intestinal microbiota Active 28-May-2020
JP-2023528397-A Bioactivating pde4 inhibitor precursors of the gut microbiota Active 28-May-2020
JP-7762168-B2 Bioactive pde4 inhibitor precursors from gut microbiota Active 28-May-2020
AU-2021280418-A1 Gut microbiota bioactivated pde4 inhibitor precursors Pending 28-May-2020
CA-3174137-A1 Gut microbiota bioactivated pde4 inhibitor precursors Active 28-May-2020 C07H17/02
To view Giiant Pharma’s complete patent history, request access »

Giiant Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Giiant Pharma Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
AmorChem Venture Capital Minority
Anges Québec Angel Group Minority
AQC Capital Venture Capital Minority
CQDM Not-For-Profit Venture Capital Minority
Crystal Pharmatech VC-Backed Company Minority
You’re viewing 5 of 10 investors. Get the full list »

Giiant Pharma FAQs

  • When was Giiant Pharma founded?

    Giiant Pharma was founded in 2014.

  • Where is Giiant Pharma headquartered?

    Giiant Pharma is headquartered in Montreal, Canada.

  • What is the size of Giiant Pharma?

    Giiant Pharma has 4 total employees.

  • What industry is Giiant Pharma in?

    Giiant Pharma’s primary industry is Drug Discovery.

  • Is Giiant Pharma a private or public company?

    Giiant Pharma is a Private company.

  • What is Giiant Pharma’s current revenue?

    The current revenue for Giiant Pharma is .

  • How much funding has Giiant Pharma raised over time?

    Giiant Pharma has raised $12.1M.

  • Who are Giiant Pharma’s investors?

    AmorChem, Anges Québec, AQC Capital, CQDM, and Crystal Pharmatech are 5 of 10 investors who have invested in Giiant Pharma.

  • Who are Giiant Pharma’s competitors?

    Edesa Biotech, Aclaris Therapeutics, Athersys, and Pfizer are competitors of Giiant Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process